Who are Butalbital, Aspirin And Caffeine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Campral, Noctan, Ativan, Glimid, Alvinol, Brevital Sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/butalbital.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Butalbital, Aspirin And Caffeine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Butalbital, Aspirin And Caffeine (BUTALBITAL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Barbiturate [EPC]. Area: Neuroscience.

marketed Barbiturate [EPC] GABA-A receptor alpha-1/beta-3/gamma-2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Butalbital, Aspirin And Caffeine (BUTALBITAL) — Actavis Labs Ut Inc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Butalbital, Aspirin And Caffeine TARGET	BUTALBITAL	Actavis Labs Ut Inc	marketed	Barbiturate [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2	1976-01-01
Campral	ACAMPROSATE	Allergan/AbbVie	marketed	acamprosate	GABA-A receptor alpha-1/beta-3/gamma-2	2004-01-01
Noctan	METHYPRYLON	Roche	marketed	methyprylon	GABA-A receptor alpha-1/beta-3/gamma-2	1982-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Glimid	GLUTETHIMIDE	Sandoz	marketed		GABA-A receptor alpha-1/beta-3/gamma-2	1976-01-01
Alvinol	ETHCHLORVYNOL	AbbVie	marketed	ethchlorvynol	GABA-A receptor alpha-1/beta-3/gamma-2	1961-01-01
Brevital Sodium	METHOHEXITAL	Ph Health	marketed	Barbiturate	GABA-A receptor alpha-1/beta-3/gamma-2	1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-01-08 — Ativan · 8999393 · Formulation · US

Sponsor landscape (Barbiturate [EPC] class)

Actavis Labs Ut Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Butalbital, Aspirin And Caffeine — Competitive Intelligence Brief. https://druglandscape.com/ci/butalbital. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing